Cormorant Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Cormorant Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-550,000	Closed	-$25.1M	–	61
2017 Q4	$25.1M	Buy	550,000 +175,000	+47%	+$8.73M	2.63%	10
2017 Q3	$16.8M	Sell	375,000 -375,000	-50%	-$12.8M	2.97%	11
2017 Q2	$22.4M	Buy	750,000 +100,000	+15%	+$2.47M	3.72%	7
2017 Q1	$14.4M	Buy	+650,000	New	+$13.9M	2.09%	17

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Cormorant Asset Management's JUNO Position: Q1 2018 in Review

Cormorant Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 550,000 shares — an estimated $25.1M sold.

Cormorant Asset Management first reported a position in JUNO in Q1 2017 and held it in 4 quarters. The position peaked at $25.1M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Cormorant Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Cormorant Asset Management sold 550,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $25.1M.
Cormorant Asset Management first reported a position in Juno Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
Cormorant Asset Management's Juno Therapeutics, Inc. position peaked at $25.1M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Cormorant Asset Management's 13F filing for Q1 2018, filed 15 May 2018.